I recall Steve Davis, Acadia's CEO, saying during presentations this year that their communication with the FDA has continued to be very good and that he didn't have any reason to be concerned about the approval process.
Also back in NEU's ASX announcement it was mentioned:
"The FDA has also informed Acadia that at this time they are not planning to hold an Advisory Committee meeting."
https://www.ncbi.nlm.nih.gov/books/NBK236088/
Extract:
This suggests to me that the safety and effectiveness data submitted by Acadia must have been clearly documented and easy to understand without further consultation by those charged with making the important approval decision.
As pointed out by others previously, the adverse effects of other FDA recently approved drugs appear to be much more substantial than those encountered during the Trofinetide trials.
So I am hoping this all points to the good news of Trofinetide by the FDA soon.
GLTAHs
- Forums
- ASX - By Stock
- NEU
- FDA
FDA, page-110
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$15.21 |
Change
-0.270(1.74%) |
Mkt cap ! $1.944B |
Open | High | Low | Value | Volume |
$15.20 | $15.33 | $15.02 | $8.268M | 543.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 700 | $15.15 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$15.24 | 220 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 334 | 15.970 |
1 | 93 | 15.700 |
1 | 8 | 15.650 |
1 | 30 | 15.200 |
2 | 718 | 15.150 |
Price($) | Vol. | No. |
---|---|---|
14.750 | 19 | 2 |
15.000 | 238 | 2 |
15.200 | 3500 | 1 |
15.210 | 100 | 1 |
15.250 | 10 | 1 |
Last trade - 16.10pm 22/08/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
SS1
SUN SILVER LIMITED
Gerard O'Donovan, Executive Director
Gerard O'Donovan
Executive Director
SPONSORED BY The Market Online